Pharma & Biotech - Page 12

President Donald Trump is expected to nominate Heidi Overton, a physician and White House domestic policy aide, to lead the Food and Drug Administration. The move, reported by a source familiar with

Aurobindo Pharma’s sterile injectables and oncology division Eugia has received a fresh FDA Warning Letter following an inspection of its Pharma Specialties facilities in Hyderabad in February. The warning letter comes after

Pharmacovigilance is undergoing a fundamental shift as artificial intelligence transforms how pharmaceutical companies detect, monitor, and respond to drug safety signals. Writing for Pharmaceutical Commerce, Updesh Dosanjh of IQVIA argues that AI-powered

Valeris, the integrated life sciences commercialization company, has appointed Scott Filosi as its new Chief Commercial Officer, effective immediately. Filosi will take responsibility for leading Valeris’s entire commercial organisation, with a sharp

Biokin Pharma’s iza-bren has recorded another significant clinical victory, meeting the primary endpoint of its Panku-Lung01 lung cancer phase 3 trial at an interim analysis. The Chinese drugmaker disclosed the result in

Australian plasma and vaccine specialist CSL posted signs of a meaningful recovery on Tuesday after a turbulent year marked by impairments, revenue downgrades, and an executive shakeup. The company’s fiscal 2026 report

Revance, a global aesthetics and skincare company, has named Janelle Wichmann as its new Chief Marketing Officer for its skincare division. Wichmann will report directly to Nadeem Moiz, who serves as Chief

IAG Cargo has added Kuala Lumpur as an approved Constant Climate station, strengthening its pharmaceutical logistics presence across Southeast Asia. The move brings the total number of approved Constant Climate locations in

Eurofins Scientific (EUFI) is expanding its high-potency active pharmaceutical ingredient manufacturing operations through its Eurofins CDMO Alphora unit based in Mississauga, Canada. The expansion targets both standard and high-potency small molecule development

Sandoz has struck a major deal with China’s Shanghai Henlius Biotechnology, securing commercialisation rights to three biosimilars currently in early development. The Swiss pharmaceutical company will pay up to $100.5 million upfront